{
 "meta": {
  "api_version": "1.0.0",
  "dataset_version": "2.0.1",
  "corpus_snapshot": "2026-10-12T22:59:14+0200",
  "source_commit": "93739c9d195dc39e47eecfabc3cab2565a2f256f",
  "license": "CC-BY-4.0",
  "cite": "Barton O. Oliver's mTOR Atlas. doi:10.5281/zenodo.22059963",
  "docs": "https://mtor-atlas.org/api/"
 },
 "data": {
  "id": "EVE-PNET",
  "claim": "Everolimus inhibits Pancreatic neuroendocrine tumor",
  "source": {
   "name": "Everolimus",
   "entity": "everolimus"
  },
  "target": {
   "name": "Pancreatic neuroendocrine tumor",
   "entity": "pancreatic-neuroendocrine-tumor"
  },
  "effect": "inhibits",
  "type": "clinical-outcome",
  "directness": "indirect",
  "timescale": "chronic",
  "compartment": null,
  "map_band": "outcome",
  "species": [
   "human"
  ],
  "mechanism": "RADIANT-3: progression-free survival more than doubled in advanced pancreatic neuroendocrine tumours.",
  "mechanism_beginner": "In a trial, everolimus more than doubled the time before advanced pancreatic neuroendocrine tumours got worse.",
  "context": null,
  "boundary": "One phase 3 trial (RADIANT-3, n=410) in advanced pancreatic neuroendocrine tumours. The result applies to that disease, stage and dose, and it is a progression-free survival result.",
  "note": null,
  "consensus_contested": false,
  "curation_contested": false,
  "contested": false,
  "confidence": {
   "mechanistic": "high",
   "human_relevance": "established",
   "consensus": "established"
  },
  "evidence": {
   "kind": "Pharmacological",
   "strongest": {
    "code": "H",
    "label": "Human study"
   },
   "supporting": [
    "YAO2011"
   ],
   "conflicting": []
  },
  "external_refs": [],
  "reviewed": null,
  "updated": null,
  "checked": null,
  "review_status": "unreviewed",
  "reviewer": null,
  "curation_status": "Proposed",
  "url": "https://mtor-atlas.org/relation/EVE-PNET/",
  "api_url": "https://mtor-atlas.org/api/v1/relations/EVE-PNET.json"
 }
}